Skip to main content


Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Fig. 1

SGLT2i usage in EXSCEL. a Percentage of exenatide arm participants taking SGLT2i at some point, by drug and by region. “Multiple” indicates use of more than one SGLT2i during the trial. b Histogram of time from first to last known SGLT2i use in the EXSCEL exenatide QW (light gray) and placebo (dark gray) arms. Note that, given lack of precise start/stop dates, this estimate of length of SGLT2i exposure represents a lower bound. c, d Time of SGLT2i initiation or matching relative to discontinuation of EQW or placebo in the propensity-matched cohorts. Blue: combination EQW+SGLT2i cohort; green: placebo cohort; red: EQW cohort

Back to article page